Theravance Biopharma, Inc. - 8-K Filing
Theravance Biopharma released a presentation on the Phase 3 CYPRESS Study of ampreloxetine for neurogenic orthostatic hypotension and FDA interactions. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $TBPH